Delandistrogene Moxeparvovec-Rokl

Introduction Overview

Generic Name

delandistrogene moxeparvovec-rokl

Brand Name

Elevidys

Dosage Form

suspension for intravenous infusion

Drug Class

Miscellaneous uncategorized agents

Pharmacokinetics

Absorption:
Elevidys is administered as a one-time intravenous infusion, which delivers the vector suspension directly into the bloodstream, bypassing gastrointestinal absorption barriers. As a gene therapy, its absorption pertains to distribution of the adeno-associated virus (AAVrh74) vector carrying the micro-dystrophin transgene into muscle cells. The intravenous route ensures rapid systemic circulation allowing efficient transduction of skeletal and cardiac muscles. Unlike traditional small molecule drugs, bioavailability relates to the vector genome reaching target tissues rather than plasma concentration metrics.

Distribution:
Following IV infusion, Elevidys's AAVrh74 vector predominantly distributes to skeletal muscles, diaphragm, and cardiac muscle, reflecting the target tissues affected by Duchenne muscular dystrophy (DMD). The tissue tropism is driven by the viral capsid’s affinity for muscle cells. Distribution to non-target organs occurs but is minimized to reduce off-target effects. The vector genome persists primarily in muscle cell nuclei, enabling expression of micro-dystrophin. Distribution extent can be affected by pre-existing antibodies to the vector which can neutralize and reduce tissue transduction.

Metabolism:
Elevidys, being a gene therapy vector, is not metabolized by classic enzymatic pathways like cytochrome P450 but is subject to intracellular processing. The AAV vector enters target muscle cells and delivers DNA that is episomal and non-integrating, not undergoing metabolism. Vector particles cleared from circulation are processed via the reticuloendothelial system. Intracellular degradation of vector particles and vector DNA occurs through normal cellular turnover mechanisms. The transgene product, micro-dystrophin protein, undergoes typical intracellular protein metabolism and degradation.

Elimination:
Elimination of Elevidys involves clearance of vector particles from plasma primarily by the mononuclear phagocyte system, including hepatic Kupffer cells and splenic macrophages. Vector genomes persist long-term in muscle nuclei but do not replicate. The vector capsid proteins degraded intracellularly and viral DNA fragments are removed by cellular nucleases. The protein expressed, micro-dystrophin, has normal protein degradation pathways. The elimination half-life of vector DNA from circulation is rapid, but tissue persistence allows prolonged transgene expression. Immune clearance mechanisms contribute to elimination and may underlie infusion-related adverse events and immune-mediated toxicities.

Dosage Forms

Available Dosage Forms:
Elevidys is available exclusively as a suspension for intravenous infusion that is administered as a one-time dose. The suspension is a sterile, liquid formulation containing the recombinant AAVrh74 vector encoding micro-dystrophin.

Dosages for Adults and Adolescents:
Elevidys dosing is weight-based. For patients weighing 10 to 70 kg, the recommended dose is 1.33 × 10^14 vector genomes per kilogram (vg/kg) or 10 mL/kg body weight. Patients weighing 70 kg or above receive a fixed maximum total dose of 9.31 × 10^15 vector genomes. This single-dose regimen is administered only once as an intravenous infusion.

Specific Patient Populations:
Elevidys is approved for patients aged 4 years and older with Duchenne muscular dystrophy who have confirmed mutations in the DMD gene and who are either ambulatory or non-ambulatory. Patients must be screened for anti-AAVrh74 antibodies prior to administration due to the risk of diminished efficacy and increased adverse events. It is contraindicated in patients with deletions in exon 8 and/or exon 9 of the DMD gene and those with elevated anti-AAVrh74 antibodies (≥1:400 titer). Prior to infusion, liver function and infection status should be evaluated, and corticosteroid therapy initiated to manage immune responses.

Clinical guidelines emphasize the importance of vaccination completion at least 4 weeks before corticosteroid initiation to minimize infection risks associated with immunosuppression during treatment.

Mechanism Of Action

Elevidys is an adeno-associated virus (AAV) vector–based gene therapy designed to deliver a functional micro-dystrophin gene to muscle cells of patients with Duchenne muscular dystrophy (DMD). DMD is caused by mutations in the DMD gene resulting in absent or non-functional dystrophin protein, a critical structural component of muscle fiber integrity. Elevidys introduces a synthetic micro-dystrophin transgene via an AAVrh74 capsid vector directly into the bloodstream, enabling targeted delivery to skeletal and cardiac muscle tissues.

Once the AAVrh74 vector enters muscle cells, it transports the micro-dystrophin DNA to the nucleus. Unlike the full-length dystrophin gene, which is too large for the vector, the micro-dystrophin gene encodes selected essential domains of dystrophin that retain key functional properties for muscle stabilization. Within muscle cell nuclei, the micro-dystrophin transgene exists episomally (not integrated into host genome), allowing transcription and subsequent translation into micro-dystrophin protein.

The expressed micro-dystrophin protein integrates into the dystrophin-associated protein complex on the inner sarcolemma of muscle fibers. This incorporation restores the linkage between the cytoskeleton and extracellular matrix, stabilizing muscle cell membranes and protecting them from mechanical stress-induced damage during contraction. Importantly, the restoration of this structural scaffold is anticipated to improve muscle strength, reduce muscle degeneration, and enhance motor function, although long-term clinical benefits are still under investigation.

Comparatively, unlike corticosteroids or antisense oligonucleotides used in DMD, Elevidys provides a genetic correction approach that replaces the missing protein rather than modulating disease pathways or splicing. Clinical trials have demonstrated vector genome delivery and micro-dystrophin expression, with ongoing evaluation of functional endpoints confirming therapeutic potential.

Pharmacological Actions

Gene therapy vector delivers functional micro-dystrophin gene to skeletal and cardiac muscle cells.
Restores expression of micro-dystrophin protein to replace absent or defective dystrophin in DMD patients.
Stabilizes muscle cell membranes by linking cytoskeleton to extracellular matrix via the dystrophin-associated protein complex.
Reduces muscle fiber degeneration and necrosis characteristic of Duchenne muscular dystrophy.
Enhances muscle strength and potentially improves motor function in affected individuals.
Elicits an immune response which may include inflammation of muscles and other infusion-related reactions.
Achieves prolonged episomal gene expression without genomic integration, reducing mutagenesis risk.
Single-dose intravenous infusion provides systemic delivery and transduction of multiple muscle groups.
Requires concurrent corticosteroid therapy to mitigate immune-mediated toxicity and inflammatory reactions.
Vector tropism is specific to muscle cells due to AAVrh74 capsid specificity.
Reduced efficacy in patients with pre-existing neutralizing antibodies to the AAVrh74 vector.
Potential to modify disease course by addressing the underlying genetic defect.
Does not produce full-length dystrophin but a shortened functional micro-dystrophin protein.
In contrast to small molecules, utilizes a biologic viral vector platform.
Ongoing research evaluates the durability and extent of functional benefit in clinical trials.

Therapeutic Or Clinical Uses

Treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older.
Indicated for both ambulatory and non-ambulatory DMD patients with confirmed DMD gene mutations.
Aimed at restoring dystrophin protein function in skeletal and cardiac muscles.
Used as a one-time gene therapy infusion to provide sustained micro-dystrophin expression.
Treatment option to potentially slow the progression of muscle degeneration inherent in DMD.
Applicable in patients without deletions in exon 8 or exon 9 of the DMD gene.
Option for patients testing negative for elevated anti-AAVrh74 antibodies.
Adjunct to multidisciplinary care strategies including physical therapy and supportive treatments.
May improve motor function and muscle strength in DMD patients over time.
Considered when corticosteroids or other standard therapies are insufficient or contraindicated.
Implemented in patients with progressive DMD to target disease at the genetic level.
Potential to reduce respiratory and cardiac complications by preserving muscle function.
Supports reduction of muscle inflammation associated with ongoing dystrophin deficiency.
Provides a novel therapeutic mechanism distinct from exon-skipping or corticosteroid agents.
Requires close monitoring post-infusion for safety and potential adverse events.

Side Or Adverse Effects

Vomiting affecting approximately 65% of patients in clinical studies.
Nausea reported in 43% of treated patients.
Acute serious liver injury observed, necessitating liver function monitoring before and after infusion.
Fever occurring in 28% of patients during or following infusion.
Low blood platelet counts (thrombocytopenia) in 8% of patients.
Infusion-related hypersensitivity reactions including anaphylaxis, rash, urticaria, and flushing.
Immune-mediated myositis causing muscle pain, tenderness, weakness, and possible respiratory difficulty.
Myocarditis with troponin-I elevations observed in some patients post-infusion.
Rigors and pyrexia as part of infusion-related adverse reaction spectrum.
Potential infections exacerbated by immunosuppressive corticosteroid co-treatment.
Gastrointestinal disturbances including vomiting and nausea during infusion periods.
Lip swelling, pruritus, and cheilitis as manifestations of hypersensitivity responses.
Tachycardia and tachypnea associated with infusion reactions requiring monitoring.
Risk of immune complex formation and systemic inflammatory responses.
Possible acute respiratory issues secondary to immune reactions.

Precautions

Perform baseline anti-AAVrh74 antibody testing; do not administer in patients with titers ≥1:400.
Assess liver function tests prior to administration and monitor weekly for three months post-infusion.
Postpone Elevidys infusion if active infection or acute liver disease is present until resolved.
Initiate systemic corticosteroid treatment one day prior to infusion to mitigate immune responses.
Monitor for infusion-related hypersensitivity reactions during and for at least three hours post-infusion.
Ensure patient immunizations are up-to-date at least four weeks prior to starting corticosteroids.
Cautiously monitor for signs of myocarditis, myositis, or other immune-mediated toxicities post-infusion.
Avoid Elevidys in patients with deletions in exon 8 and/or exon 9 of the DMD gene.
Evaluate patients for signs of infection given risks during corticosteroid-induced immunosuppression.
Inform patients to report muscle pain, weakness, difficulty swallowing or breathing immediately.
Closely observe liver parameters and consider specialist consultation if liver injury suspected.
Adjust corticosteroid regimen as clinically indicated during the peri-infusion period.
Assess contraindications thoroughly and ensure detailed patient history prior to administration.
Prepare to manage potential anaphylaxis and infusion-related emergencies in clinical settings.
Educate patients and caregivers on recognizing side effects and adhering to monitoring schedules.

Warnings

Infusion-related reactions including severe hypersensitivity and anaphylaxis may occur during or shortly after infusion.
Acute serious liver injury has been reported; liver function must be monitored before and after treatment.
Immune-mediated myositis can cause severe muscle inflammation and requires immediate medical attention.
Acute myocarditis with troponin elevations has been observed; chest pain and shortness of breath warrant urgent evaluation.
Pre-existing immunity to AAVrh74 vector reduces dosing efficacy and increases risk of adverse effects.
Patients receiving corticosteroids may have increased susceptibility to infections; monitor carefully.
Immunization status should be optimized prior to corticosteroid and Elevidys treatment to reduce infection risks.
Use is contraindicated in patients with certain deletions (exon 8 and/or exon 9) in the DMD gene.
Potential for severe immune reactions necessitates prolonged post-infusion observation (minimum 3 hours).
Risk of liver dysfunction is heightened in patients with pre-existing hepatic impairment or viral hepatitis.
Systemic corticosteroids required for immune modulation may cause their own adverse effects.
Anaphylactic reactions may present with respiratory distress, rash, and hemodynamic instability.
Monitoring for cardiac adverse events is essential due to myocarditis risk.
Delay Elevidys administration in patients with active infections until resolution.
Report and manage infusion-related symptoms promptly to minimize morbidity.

Contraindication

Presence of elevated anti-AAVrh74 total binding antibodies with titers ≥1:400.
Patients with deletions in exon 8 and/or exon 9 of the DMD gene.
Active acute liver disease including acute viral hepatitis at the time of intended infusion.
Known hypersensitivity to any component of the Elevidys suspension or AAVrh74 vector.
Patients unable to receive corticosteroid therapy concomitantly for immune modulation.
Individuals with severe uncontrolled infections contraindicating immunosuppressive treatment.
Patients with a history of anaphylaxis to similar gene therapy vectors or viral vector components.
Pre-existing severe hepatic impairment contraindicating safe administration and monitoring.
Patients who have previously received AAVrh74-based gene therapy to avoid cumulative toxicity.
Children under 4 years of age due to lack of safety and efficacy data.
Individuals with hypersensitivity to excipients present in the formulation.
Patients with concurrent illnesses posing unacceptable risk for gene therapy treatment.
Co-administration with agents that may exacerbate hepatic or immune toxicities without close supervision.
Lack of confirmed mutation in the DMD gene as Elevidys targets specific genetic defects.
Non-ambulatory patients outside of accelerated approval criteria or clinical trial settings.

Drug Interactions

Concomitant corticosteroid therapy required to prevent immune-mediated adverse effects; dosing should be managed carefully.
Vaccinations should be completed at least 4 weeks prior to initiation of corticosteroid regimen due to immunosuppression.
Immunosuppressants potentially increase infection risk when given with Elevidys and corticosteroids.
Pre-existing antibodies to AAVrh74 can neutralize Elevidys efficacy and increase adverse reactions.
Drugs affecting liver function may influence safety profile; monitor hepatic enzymes closely.
Concomitant use of hepatotoxic drugs should be cautiously evaluated given liver injury risk.
No significant pharmacokinetic interactions with traditional small molecules expected due to gene therapy nature.
Potential additive immunosuppressive effect with other immunomodulatory agents increasing infection risk.
Live vaccines should be avoided during and shortly after corticosteroid treatment due to immune suppression.
Agents that induce or inhibit immune function may alter therapeutic outcomes and adverse event profiles.
Drugs affecting cardiac conduction or causing cardiotoxicity should be used cautiously considering myocarditis risk.
No known cytochrome P450 interactions, but clinical monitoring recommended given novel mechanism.
Avoid administration in combination with other gene therapies targeting muscular dystrophy unless under clinical guidance.
Interactions with anticoagulants or antiplatelet agents require monitoring if liver injury affects synthesis of clotting factors.
Potential interaction with agents affecting vector clearance or immune recognition has been observed in research settings.

Preparations Of The Drug

Elevidys is supplied as a sterile suspension for intravenous infusion, shipped at temperatures ≤ −60ºC (−76ºF).
Can be refrigerated at 2°C to 8°C (36ºF to 46ºF) for up to 14 days in the upright position before administration.
Do not refreeze the product after thawing; preparation requires careful temperature control.
Do not shake the suspension to avoid compromising the viral vector integrity.
Once brought to room temperature, do not return to refrigeration.
Handle according to local biological waste regulations due to viral vector content.
Vial contains the specific dose adjusted based on patient body weight; dosing volume calculated accordingly.
Preparation and administration require aseptic technique and trained healthcare professionals.
Premedication with corticosteroids and pre-infusion assessments are integral to safe administration.
Single-use vial; any unused portion must be discarded to prevent contamination and loss of potency.
Provision includes Patient Information Leaflet and Package Insert with detailed handling and administration instructions.
Requires specialized storage and transport equipment to maintain stability during shipping and handling.
Manufactured by Sarepta Therapeutics, ensuring compliance with FDA gene therapy regulations and quality standards.
Preparation protocols require coordination with hospital pharmacy and infusion services.
Must be administered only in healthcare settings prepared to manage possible infusion-related reactions.